D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Investing.com - Leerink Partners upgraded 908 Devices Inc . (NASDAQ:MASS) from Market Perform to Outperform on Tuesday, while raising its price target to $12.00 from $5.00. The upgrade comes as the stock has shown remarkable momentum, delivering a 146% return over the past six months, according to InvestingPro data.
The upgrade follows 908 Devices’ transformation into a forensics and threat detection pure-play after its recent life sciences divestiture, positioning the company to potentially exceed its 20% growth expectations for 2026. The company has demonstrated strong revenue growth of 32.85% over the last twelve months, though InvestingPro analysis indicates current year sales may face some headwinds.
The company currently guides for 15% pro-forma growth this year but anticipates acceleration in 2026, supported by $1.7 billion in federal grant appropriations and upcoming product launches including new handheld devices XplorIR, VipIR, and ProtectIR.
908 Devices serves an estimated $2.5 billion market by 2027 and targets positive adjusted EBITDA by the fourth quarter of 2025, with profitability expected to increase in 2026 under its new lean structure and lower-cost facilities.
The company currently holds $118 million in cash and expects to maintain over $100 million by the end of 2026, with shares trading at approximately 1x EV/Sales based on 2026 estimates.
In other recent news, 908 Devices Inc. announced its financial results for the second quarter of 2025. The company reported a revenue of $13 million, which exceeded the forecast of $12.17 million and marked a 14% increase from the previous year. Despite this revenue growth, the earnings per share (EPS) did not meet expectations, registering at -$0.37 against the anticipated -$0.17. These developments highlight a mixed performance for the quarter. Analysts have not provided any upgrades or downgrades following the earnings release. The financial results have drawn attention to the company’s ongoing efforts and challenges in meeting market expectations. These recent developments are crucial for investors evaluating the company’s financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.